The presence of diagnostic markers, such as 1p/19q codeletion or the loss of expression of ATRX and TP53 tumor suppressors, aids in defining the diagnoses of oligodendroglioma or IDH-mutant astrocytoma, respectively. This evidence concerns the gene IDH2 and neoplasm.